User profiles for Riccardo Corbellari

Riccardo Corbellari

PhD, University of Trento
Verified email at unitn.it
Cited by 131

[PDF][PDF] Proteome‐minimized outer membrane vesicles from Escherichia coli as a generalized vaccine platform

…, SJ Isaac, M Grigolato, R Corbellari… - Journal of …, 2021 - Wiley Online Library
Because of their potent adjuvanticity, ease of manipulation and simplicity of production Gram‐negative
Outer Membrane Vesicles OMVs have the potential to become a highly effective …

[HTML][HTML] Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody

…, M Matasci, N Favalli, R Corbellari… - … for ImmunoTherapy of …, 2022 - ncbi.nlm.nih.gov
Background In this study, we describe the generation of a fully human monoclonal antibody (named
‘7NP2’) targeting human fibroblast activation protein (FAP), an antigen expressed in …

[HTML][HTML] Bacterial Outer Membrane Vesicles as a Platform for the Development of a Broadly Protective Human Papillomavirus Vaccine Based on the Minor Capsid …

…, E Caproni, M Benedet, M Tomasi, R Corbellari… - Vaccines, 2023 - mdpi.com
Human papillomaviruses (HPVs) are a large family of viruses with a capsid composed of the
L1 and L2 proteins, which bind to receptors of the basal epithelial cells and promote virus …

[HTML][HTML] Vaccination with a FAT1-derived B cell epitope combined with tumor-specific B and T cell epitopes elicits additive protection in cancer mouse models

…, S Valensin, M Tomasi, S Stupia, R Corbellari… - Frontiers in …, 2018 - frontiersin.org
Human FAT1 is overexpressed on the surface of most colorectal cancers (CRCs) and in
particular a 25 amino acid sequence (D8) present in one of the 34 cadherin extracellular repeats …

A novel antibody–IL15 fusion protein selectively localizes to tumors, synergizes with TNF-based immunocytokine, and inhibits metastasis

R Corbellari, M Stringhini, J Mock, T Ongaro… - Molecular cancer …, 2021 - AACR
IL15 is an immunostimulatory cytokine that holds promises for cancer therapy, but its
performance (alone or as partner for fusion proteins) has often been limited by suboptimal …

The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors

R Corbellari, L Nadal, A Villa, D Neri… - Anti-cancer …, 2020 - journals.lww.com
Corbellari, Riccardo a,,b,,* ; Nadal, Lisa a,,b,,* ; Villa, Alessandra b ; Neri, Dario c ; De Luca,
Roberto … * Riccardo Corbellari and Lisa Nadal contributed equally to the writing of this article. …

[HTML][HTML] A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo

T Ongaro, B Gouyou, M Stringhini, R Corbellari… - Oncotarget, 2020 - ncbi.nlm.nih.gov
The targeted delivery of interleukin-2 to the tumor is gaining attention as an avenue to
potentiate the action of T and NK cells at the site of disease. We have previously described the …

[HTML][HTML] Anti-tumor Efficacy of in situ Vaccination Using Bacterial Outer Membrane Vesicles

E Caproni, R Corbellari, M Tomasi, SJ Isaac… - Cancers, 2023 - mdpi.com
Simple Summary In situ vaccination (ISV) envisages the intratumoral injection of
immunostimulatory molecules, which inflame the tumor and induce anti-tumor immune responses. …

[HTML][HTML] Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine

…, A Gagliardi, I Zanella, M Benedet, R Corbellari… - Vaccines, 2023 - mdpi.com
The vaccination campaign against SARS-CoV-2 relies on the world-wide availability of
effective vaccines, with a potential need of 20 billion vaccine doses to fully vaccinate the world …

Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors in vivo

L Nadal, R Corbellari, A Villa, T Weiss, M Weller, D Neri… - MAbs, 2020 - Taylor & Francis
Antibody-based delivery of bioactive molecules represents a promising strategy for the
improvement of cancer immunotherapy. Here, we describe the generation and characterization of …